Stay updated with breaking news from தெளிவு ஒஸாவ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
After their startups were acquired, 3 biotech executives try a second act with San Diego's 858 Therapeutics sandiegouniontribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegouniontribune.com Daily Mail and Mail on Sunday newspapers.
Lycia Therapeutics Announces $70 Million Series B Financing globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Stablix Therapeutics launches today with a $63 million series A to bankroll work on protein stabilization in the hopes of treating rare diseases, cancer and immunological disorders. ....
Capsida Biotherapeutics Debuts with $140 Million of Capital - Versant, Westlake Village BioPartners launch next-generation gene therapy company with $50 million Series A - - Collaboration with AbbVie provides $90 million in up front and equity investment capital to create tissue-targeted gene therapies for three CNS disease targets - News provided by Share this article Share this article THOUSAND OAKS, Calif., April 29, 2021 /PRNewswire/ Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases. In addition to a $50 million Series A commitment from the two firms, Capsida also announced a multi-year strategic collaboration and option agreement with AbbVie that provides $90 million in up front and equity invest ....
Versant Ventures Raises $950 Million Across Three Vehicles $140 million companion fund to boost selected early high-performers $250 million opportunity fund for later-stage rounds Versant Ventures today announced $950 million in additional capital allocated across a platform of three separate vehicles. These included Versant Venture Capital VIII, a $560 million primary global biotech fund; Versant Voyageurs II, a $140 million booster fund; and Versant Vantage II, a $250 million later-stage opportunity fund. All three funds exceeded their initial targets and were heavily oversubscribed. The capital from existing investors and a select number of new top-tier limited partners will support Versant s highly successful biotech investment strategy and portfolio construction model. ....